Navigation Links
Algeta Demonstrates Targeted Cancer-killing Potential of Novel,Alpha Particle Linked Antibodies in Leading Medical Journal Blood

p>Therapy with 227Th-rituximab was significantly more effective than the control radioimmunoconjugate 227Th-trastuzumab, which does not bind CD20, and the standard beta particle emitting radioimmunoconjugate for CD20-positive lymphoma, Zevalin® (90Y-tiuxetan-ibritumomab), which is marketed by Biogen-Idec.

Dr Thomas Ramdahl, President and CEO of Algeta commented: "This important paper provides more evidence of the potential of alpha particle based molecules for targeted cancer therapy. The publication follows excellent Phase II clinical data for our lead product Alpharadin (radium-223) in prostate cancer, which was published recently in the Lancet Oncology. We are working with collaborators to validate our TH-1 technology and are looking for further partnering opportunities with companies that have interesting cancer-targeting molecules that would benefit from this approach."

Reference

Targeted cancer therapy with a novel low dose rate alpha-emitting radioimmunoconjugate (2007) Dahle, J. et al. (2007)

http://bloodjournal.hematologylibrary.org/cgi/ content/abstract/blood-2007-01-066803v1

###

For further information, please contact

Dr. Thomas Ramdahl, CEO +47 23 00 79 90 / +47 913 91 458 (mob) Geir Christian Melen, CFO +47 23 00 79 90 / +47 913 02 965 (mob) post@algeta.com

Dr. Mark Swallow / Helena +44 (0)207 638 9571 Galilee mark.swallow@citigatedr.co.uk Citigate Dewe Rogerson

About Algeta

Algeta ASA (www.algeta.com) is a Norwegian cancer therapeutics company built on world-leading, proprietary technology.

Algeta is developing new, targeted cancer therapeutics that harness the unique characteristics of alpha particle emitters and are pote
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Algeta to Present Phase II Clinical Study Data for Alpharadin in Prostate Cancer at ASCO
2. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
3. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
4. New Research Demonstrates Broad Efficacy of Azixa (MPC-6827) Against Multiple Tumor Types and in Drug Resistant Cell Lines
5. Gerons Telomerase Inhibitor Cancer Drug Demonstrates Good Pharmacokinetics and Tolerability in Phase I/II Trial
6. Frova Phase III Study Data Demonstrates That Short-Term Prevention Treatment Reduces Frequency and Severity of Menstrual Migraine
7. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
8. Newly Published Data Demonstrates Superiority of Cipralex Over Duloxetine for Acute Treatment of Depression
9. Introgens Advexin Demonstrates Clinical Benefit in Inherited Cancer
10. Prostate Cancer: Clinical Study Demonstrates Superior Efficacy of Docetaxel Chemotherapy
11. Lpath Demonstrates First-in-Class AMD Results With Its Lead Drug Candidate, Sphingomab
Post Your Comments:
(Date:1/15/2014)... 2014  Celsion Corporation (the "Company") (NASDAQ: CLSN ... institutional investors to purchase an aggregate of approximately $15 ... registered direct offering, led by a dedicated health care ... agreements with these investors pursuant to which the Company ...
(Date:1/15/2014)... DUBLIN , January 15, 2014 Shire plc ... waived the Office of Fair Trading (OFT) approval condition to the ... Incorporated (NASDAQ: VPHM).   As a result of the ... Shire expects to complete the tender offer on January 24, 2014 ...
(Date:1/15/2014)... , January 15, 2014 BreedIT ... the exclusive worldwide distributor of highly sophisticated agro-breeding solutions ... January 7, 2014, the Company,s board of directors appointed ... as its new member of the board. ...
Breaking Medicine Technology:Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3
... Bolder BioTechnology, Inc. today announced that it has ... (SBIR) grant totaling $600,000 from the National Institute of ... of Health (NIH).  The grant will be used to ... analog to accelerate platelet recovery and improve survival in ...
... Technologies Foster Better Informed Consumers, Greater Interest in Personal... -- PHILADELPHIA, Pennsylvania, August 18, 2010 ... ... lpUnit=,PRN,; --> ... var s = ,; var first_result; // Results are keyed by longUrl, so we need to ...
Cached Medicine Technology:Bolder BioTechnology Announces $600,000 Grant from NIH to Study Long-Acting IL-11 Analog in Treating Acute Radiation Syndrome 2Advanced Web-Based Medical Technologies Foster Better Informed Consumers, Greater Interest in Personal Health Care 2Advanced Web-Based Medical Technologies Foster Better Informed Consumers, Greater Interest in Personal Health Care 3Advanced Web-Based Medical Technologies Foster Better Informed Consumers, Greater Interest in Personal Health Care 4Advanced Web-Based Medical Technologies Foster Better Informed Consumers, Greater Interest in Personal Health Care 5Advanced Web-Based Medical Technologies Foster Better Informed Consumers, Greater Interest in Personal Health Care 6Advanced Web-Based Medical Technologies Foster Better Informed Consumers, Greater Interest in Personal Health Care 7Advanced Web-Based Medical Technologies Foster Better Informed Consumers, Greater Interest in Personal Health Care 8
(Date:4/18/2014)... 18, 2014) ― A new study in the ... in health-related Google searches reveals a recurring pattern that ... , Investigators from San Diego State University, the ... Campaigns, analyzed "healthy" Google searches (searches that included the ... originating in the U.S. from 2005 to 2012. They ...
(Date:4/17/2014)... genetic variant specifically associated with the risk of ... per cent of all breast cancer cases. , ... sub-type, called invasive lobular carcinoma, gives researchers important ... kind of breast cancer, which can be missed ... in the journal PloS Genetics , was ...
(Date:4/17/2014)... the University of California, San Diego School of Medicine ... have suffered a recent major loss are more likely ... , The study is published in this month,s issue ... , Because compassionate behaviors are associated with better health ... insights into ways to improve the outcomes of individuals ...
(Date:4/17/2014)... New Rochelle, NY, April 17, 2014U.S. military personnel ... "blast plus impact" concussive traumatic brain injury (TBI) ... were evacuated for other medical reasons. Differences in ... and depression 6-12 months after injury are reported ... , a peer-reviewed journal from Mary Ann Liebert, ...
(Date:4/17/2014)... April 17, 2014 By discovering a new mechanism ... a stroke, researchers at UC Irvine and the Salk ... may limit or prevent stroke-induced brain damage. , A ... cause of death and primary reason for disability in ... a stroke and lets blood-borne material into the brain, ...
Breaking Medicine News(10 mins):Health News:New research shows people are thinking about their health early in the week 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 3Health News:The ilk of human kindness 2Health News:Long-term effects of battle-related 'blast plus impact' concussive TBI in US military 2Health News:Study IDs new cause of brain bleeding immediately after stroke 2
... Denise Mann HealthDay Reporter , TUESDAY, Nov. 15 (HealthDay ... away, but three kiwis just might help, at least according to ... lower blood pressure levels. Men and women with mildly high ... weeks had systolic blood pressure levels that were 3.6 millimeters ...
... TUESDAY, Nov. 15 (HealthDay News) -- New research suggests that ... people see you at first glance in terms of your ... your personality, especially in terms of empathy. Or it,s possible ... you act. On the other hand, the research is based ...
... stroke patients have not had a great track record ... Zealand focused on Maori and Pacific populations shows how ... and families in charge can make a difference to ... in the journal Clinical Rehabilitation , which is ...
... HealthDay Reporter , TUESDAY, Nov. 15 (HealthDay News) -- ... than healthier individuals to suffer a first heart attack, according to ... or no risk factors are more likely to die from that ... factors present much earlier in age than patients with ...
... 15 (HealthDay News) --,Low levels of vitamin D may put ... to one of several new studies on the important nutrient. ... 2,000 healthy, postmenopausal white women aged 45 to 58, researchers ... had more risk factors for heart disease than 1,225 women ...
... is the most common infection following heart surgery, a new ... occur about two weeks after an operation -- a week ... findings Tuesday at the American Heart Association (AHA) annual meeting ... find," study author Dr. Michael Acker, chief of cardiovascular surgery ...
Cached Medicine News:Health News:Got High Blood Pressure? Kiwi Fruit May Help 2Health News:Got High Blood Pressure? Kiwi Fruit May Help 3Health News:Does a Gene Make People Seem Kinder? 2Health News:Does a Gene Make People Seem Kinder? 3Health News:Putting stroke patients in charge improves quality of life 2Health News:Putting stroke patients in charge improves quality of life 3Health News:Fewer Disease Risk Factors Yet More Fatal Heart Attacks 2Health News:Fewer Disease Risk Factors Yet More Fatal Heart Attacks 3Health News:Low Vitamin D May Increase Stroke, Heart Attack Risk in Women 2Health News:Pneumonia Most Common Infection After Heart Surgery 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: